01—Abstract
Summary
Summary of the 10-Q filed November 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. reported third-quarter fiscal 2026 revenues of $4.63 billiona, up 3.6% from $4.47 billion a year earlier, and operating income of $553 million, up 3.4%.
Net income attributable to common stockholders was $410 millionb, and diluted EPS was $3.28 versus $2.82. For the nine months, revenues rose 4.8% to $13.59 billion, but operating income fell 3.7% to $1.58 billion, and diluted EPS was $8.67 versus $8.62. Results were mixed by segment: Homeland grew sharply, helped by the Entrust acquisition, while Health revenue fell 11.7% in the quarter, with operating income down 25.9%, due to reduced managed health services volumes and lower incentive fees.
The balance sheet changed meaningfully during the period. Leidos completed the approximately $2.4 billionc cash acquisition of Entrust on March 27, 2026, funded partly by $1.4 billion of new senior notes. Total debt rose to $6.0 billion from $4.6 billion at fiscal year-end, and cash fell to $630 million.
Goodwill increased to $7.7 billiond. Nine-month operating cash flow improved to $1.62 billion from $1.26 billion, and the company returned capital through $766 million of open-market buybacks and dividends of $0.43 per share each quarter. After quarter-end, on October 5, 2026, Leidos closed the contribution of its Security Enterprise Solutions and Industrial Automation businesses into a joint venture with Altaris, retaining a 41.5% non-controlling interest.
The company expects a non-operating gain of approximately $100 million in the fourth quarter, and it expects fourth-quarter revenues to be lower as a result. Total net bookings were $13.7 billion for the nine months, and total backlog stood at $49.6 billion. The filing also discloses an open Department of Justice Antitrust Division grand jury investigation, for which the company says it cannot currently estimate any potential liability.
02—Key points
Key Highlights
- Q3 FY2026 revenue of $4.63 billion (up 3.6%) and operating income of $553 million (up 3.4%); diluted EPS of $3.28 versus $2.82 a year earlier.
- Nine-month operating income declined 3.7% to $1.58 billion despite 4.8% revenue growth to $13.59 billion; the effective tax rate fell to 14.3% in Q3 from 23.8%.
- Health segment weakened: Q3 revenue fell 11.7% to $1.07 billion and operating income fell 25.9%, reflecting reduced managed health services volumes and lower incentive fees.
- Homeland revenue rose 32.1% in Q3 to $1.02 billion, including $142 million from the Entrust acquisition.
- Entrust acquisition for $2.4 billion in cash closed March 27, 2026; total debt rose to $6.0 billion from $4.6 billion and cash fell to $630 million.
- Total backlog of $49.6 billion and remaining performance obligations of $21 billion; nine-month net bookings of $13.7 billion versus $11.9 billion a year earlier.
- SES Business divestiture closed October 5, 2026, with Leidos retaining 41.5%; a non-operating gain of approximately $100 million is expected in Q4 FY2026.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2027, Leidos Holdings kept $0.09.
- Revenue$4.62B100.0%
- Cost of revenue−$3.81B82.5%
- Gross profit$807.0M17.5%
- Operating costs−$254.0M5.5%
- Operating income$553.0M12.0%
- Interest, other & tax−$143.0M3.1%
- Net income$410.0M8.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2027filed November 3, 2026Financial Statements
Q3 FY2027 against Q3 FY2026
| Line item | Q3 FY2027Q3 FY2026 | Change |
|---|---|---|
| Revenue | $4.62B$4.45B | +3.8% |
| Cost of Revenue | $3.81B$3.65B | +4.4% |
| Gross Profit | $807.00M$801.00M | +0.7% |
| SG&A Expenses | $262.00M$290.00M | −9.7% |
| Operating Income | $553.00M$535.00M | +3.4% |
| Net Income | $410.00M$367.00M | +11.7% |
| EPS (Basic) | $3.31$2.87 | +15.3% |
| EPS (Diluted) | $3.28$2.82 | +16.3% |
| Shares Outstanding (Basic) | 124.00M128.00M | −3.1% |
| Shares Outstanding (Diluted) | 125.00M130.00M | −3.8% |
05—Questions
Frequently Asked Questions
How did Leidos perform in the third quarter of fiscal 2026?
Revenues were $4.63 billion, up 3.6% from $4.47 billion. Operating income was $553 million, up 3.4%, and net income attributable to Leidos common stockholders was $410 million versus $367 million. Diluted EPS was $3.28 compared with $2.82.
Why did nine-month operating income decline despite revenue growth?
Nine-month operating income fell 3.7% to $1.58 billion while revenues rose 4.8%. Corporate expense increased to $100 million, mainly from higher acquisition and integration costs, and the Health segment's operating income declined 15.0% on lower managed health services volumes. Acquisition, integration and restructuring costs were $74 million for the nine months versus $10 million a year earlier.
What is the financial impact of the Entrust acquisition and the SES divestiture?
Entrust, acquired for $2.4 billion in cash, contributed $142 million of Q3 revenue and $294 million for the nine months within Homeland. The preliminary purchase price allocation includes $1.7 billion of goodwill and $630 million of intangible assets, and is not yet final. The SES Business was contributed to a joint venture on October 5, 2026; Leidos retains a 41.5% non-controlling interest and expects a roughly $100 million non-operating gain in Q4, with lower fourth-quarter revenues than otherwise expected.
How is the company's liquidity and leverage position?
Cash and cash equivalents were $630 million at October 2, 2026. Total debt was $6.0 billion, up from $4.6 billion, after issuing $600 million of 4.10% notes due 2029 and $800 million of 5.00% notes due 2036. The $1.5 billion revolving facility and $1.5 billion commercial paper program had no borrowings or notes outstanding, and the company stated it was in compliance with all financial covenants.
What legal and regulatory risks does the filing disclose?
The company received a federal grand jury subpoena in August 2022 from the Department of Justice Antitrust Division related to three U.S. government procurements, and it is cooperating and conducting an internal investigation. The filing states it is not possible at this time to determine or reasonably estimate any fines, penalties or further liabilities. Defense Contract Audit Agency audits remain open for fiscal 2025 and later, and federal funding is secured only through December 11, 2026, under a continuing resolution.
06—Continue